Advertisement
Wednesday, Dec 08, 2021
Outlook.com
Outlook.com

WHO Technical Group To Meet On Oct 26 To Consider EUL Of Bharat Biotech’s Covaxin

If a product submitted for assessment is found to meet the criteria for listing, the WHO will publish the results widely.

WHO Technical Group To Meet On Oct 26 To Consider EUL Of Bharat Biotech’s Covaxin
Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine. The WHO said it began rolling data of the vaccine on July 6. | Representational Image
WHO Technical Group To Meet On Oct 26 To Consider EUL Of Bharat Biotech’s Covaxin
outlookindia.com
2021-10-18T07:40:35+05:30

The World Health Organization's technical advisory group will meet on October 26 to consider the Emergency Use Listing (EUL) of Hyderabad-based Bharat Biotech’s Covid-19 vaccine, Covaxin.

World Health Organization Chief Scientist Soumya Swaminathan in a tweet on Sunday said, “The technical advisory group will meet on Oct 26th to consider EUL for #Covaxin. @WHO has been working closely with @BharatBiotech to complete the dossier. Our goal is to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere.

 Earlier this month, the WHO said Bharat Biotech “has been submitting data to WHO on a rolling basis and submitted additional information at the WHO's request on September 27. The WHO experts are currently reviewing this information and if it addresses all questions raised, the WHO assessment will be finalised next week."

 Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine. The WHO said it began rolling data of the vaccine on July 6.

 Rolling data allows the WHO to start its review right away, as information continues to come in, to accelerate the overall review process. According to the WHO, submissions for pre-qualification or listing under the emergency use procedure are confidential.

 If a product submitted for assessment is found to meet the criteria for listing, the WHO will publish the results widely.

 Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on the data meeting the WHO's criteria, according to the agency.

The indigenously developed Bharat Biotech's Covaxin is one of the six vaccines that have received emergency use authorisation from India's Drug Regulator and is being used in the nationwide anti-Covid-19 inoculation programme along with Covishield and Sputnik V.

Bharat Biotech recently said it submitted all data pertaining to Covaxin to the WHO for EUL and is awaiting feedback from the global health watchdog.

"#COVAXIN clinical trial data was fully compiled and available in June 2021. All Data submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback," Bharat Biotech had tweeted last month.

"We are diligently working with the WHO to obtain EUL at the earliest,” the company had said on Tuesday. 

 According to Johns Hopkins University, the coronavirus has claimed 4,897,386 lives along with 240,559,605 confirmed cases across the world so far.

(PTI inputs)

Advertisement

Outlook Newsletters

Advertisement
Advertisement
Advertisement

Read More from Outlook

Why A Democratic India Must Junk Draconian AFSPA

Why A Democratic India Must Junk Draconian AFSPA

Experts believe the AFSPA has caused more harm to the Indian State in insurgency-hit areas than mitigating problems. Here’s why.

Nagaland Ambush: Not Just AFSPA, It’s Time To Do Away With Most Special Laws

Nagaland Ambush: Not Just AFSPA, It’s Time To Do Away With Most Special Laws

It may be time for India to uphold human dignity, take a hard look at some of its regressive laws like AFSPA which includes Special Laws that authorises detention without trial.

Ashes 2021-22: Australia Start Favourites - Statistical Preview

Ashes 2021-22: Australia Start Favourites - Statistical Preview

The Gabba has been like a fortress for Australia in the Ashes. The Aussies have a 12-4 win-loss record in Brisbane and they will do everything to protect that record.

Why AFSPA In Jammu And Kashmir Is Not Just A Defence Act

Why AFSPA In Jammu And Kashmir Is Not Just A Defence Act

Has the AFSPA become an ideological Act, a tool to revise Kashmir history? Many analysts believe so.

Advertisement